Transition Bio, Inc.

CAMBRIDGE, MA · Founded 2020 · Biotech · Private

End-to-end condensate drug discovery platform using biomolecular condensate technology to identify and develop therapeutics

Claim this profile

Follows are private to you and power your alerts

Updated · transitionbio.com

Sector
Biotech
Headquarters
CAMBRIDGE, MA
Founded
2020
Latest Form D
$13.3M, Oct 2024
Total capital
$49.8M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$49.8M
3 Form D · last Oct 2024
24 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
3 pending

Capital timeline

202220232024FEDERAL ↑EQUITY ↓Cumulative $49.8M1st Form D$30.6M2nd Form D$6M3rd Form D$13.3M
202220232024FEDERAL ↑EQUITY ↓Cumulative $49.8M1st Form D$30.6M2nd Form D$6M3rd Form D$13.3M

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$13.3M
  • Private capital raisedForm D · SEC · 2nd filing$6M
  • Private capital raisedForm D · SEC · 1st filing$30.6M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Al SandrockDirectorNamed in SEC Form D filings
  • Connor McDermottDirectorNamed in SEC Form D filings
  • George MartinExecutive Officer, DirectorNamed in SEC Form D filings
  • Gregory L. MillerExecutive Officer, DirectorNamed in SEC Form D filings
  • Kathy K. YiDirectorNamed in SEC Form D filings
  • Martin L. KulanderExecutive OfficerNamed in SEC Form D filings
Show all 12 people
  • Paxton MajorDirectorNamed in SEC Form D filings
  • Preet MakkarExecutive OfficerNamed in SEC Form D filings
  • Robert WeeksDirectorNamed in SEC Form D filings
  • Samuel CohenDirectorNamed in SEC Form D filings
  • Stephanie TorruellaExecutive OfficerNamed in SEC Form D filings
  • Tuomas L. KnowlesExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 3
  • PendingHigh-throughput Condensate Modulator ScreenUSPTOApplication PCTUS2024044811
  • PendingHigh-throughput Condensate Modulator ScreenUSPTOApplication 63536319
  • PendingHigh-throughput Condensate Modulator ScreenUSPTOApplication 19514275
  • TRILOGIC PHARMA LLCSimilar federal contract value in Biotech · null in contracts
  • OASIS PHARMACEUTICALS, LLCSimilar federal contract value in Biotech · null in contracts
  • ZymeworksSimilar federal contract value in Biotech · null in contracts
  • Spinnaker Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
  • Noetik Inc.Similar federal contract value in Biotech · null in contracts
  • Xanadu Bio, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .